Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Publications note now clarifies PubMed auto-fill for publications and adds a Revision: v3.3.2 indicator; the previous PubMed wording and the Revision: v3.2.0 reference were removed.SummaryDifference0.1%

- Check28 days agoChange DetectedDeleted the government funding operating status notice from the page; core study content, eligibility criteria, and location information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedNo significant changes; only minor formatting differences observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedAdds a government-status notice and a new software version (v3.2.0); removes the old version tag (v3.1.0).SummaryDifference2%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.